Search - tctmd.com

Displaying 61 - 80 of 109

Sort: Relevancy | Date

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

Todd Neale

August 30, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Daily News

New-Generation DES Work Just Fine in Women With Acute MI

Todd Neale

June 29, 2017

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

Advertisement

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Long-term Absorb BVS Data Continue to Disappoint

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

ESC Updates Guidelines for Treating STEMI Patients

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Boston Scientific Scraps Biodegradable Scaffold Program

New-Generation DES Work Just Fine in Women With Acute MI

Use of DAPT Score Following PCI Validated in PRODIGY Study

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content